Ng, Bryan http://orcid.org/0000-0002-6819-0176
Vowles, Jane
Bertherat, Féodora http://orcid.org/0000-0002-6717-6663
Abey, Ajantha http://orcid.org/0000-0003-0484-8001
Kilfeather, Peter
Beccano-Kelly, Dayne
Stefana, M. Irina
O’Brien, Darragh P. http://orcid.org/0000-0003-4924-7795
Bengoa-Vergniory, Nora
Carling, Phillippa J.
Todd, John A.
Caffrey, Tara M.
Connor-Robson, Natalie
Cowley, Sally A. http://orcid.org/0000-0003-0297-6675
Wade-Martins, Richard
Funding for this research was provided by:
Agency for Science, Technology and Research (N/A)
Parkinson's UK (J-1403, J-1403, J-1403, J-1403)
Parkinson's UK
Parkinson's UK
Oxford University | Oxford Martin School, University of Oxford (LC0910-004)
Parkinson's UK
RCUK | Medical Research Council (MR/L023784/2, MR/M024962/1)
Article History
Received: 14 February 2023
Revised: 22 January 2024
Accepted: 24 January 2024
First Online: 15 February 2024
Competing interests
: The authors declare no competing interests.
: The ethics information for the SBAd-03-01 parental iPSC line can be found from the Lonza product page (CC-2511) where the source dermal fibroblast was obtained, whereas that for the SFC856-03-04 parental iPSC line was approved by the National Health Service, Health Research Authority, National Research Ethics Service Committee South Central, Berkshire, United Kingdom, Research Ethics Committee 10/H0505/71.